JP5414972B2 - 病原体感染の検出のための組成物および方法 - Google Patents

病原体感染の検出のための組成物および方法 Download PDF

Info

Publication number
JP5414972B2
JP5414972B2 JP2006546204A JP2006546204A JP5414972B2 JP 5414972 B2 JP5414972 B2 JP 5414972B2 JP 2006546204 A JP2006546204 A JP 2006546204A JP 2006546204 A JP2006546204 A JP 2006546204A JP 5414972 B2 JP5414972 B2 JP 5414972B2
Authority
JP
Japan
Prior art keywords
polypeptide
lysozyme
xaa xaa
xaa
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006546204A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008502318A (ja
Inventor
フランソワ ハビエール バルテット，
カサデバイユ， フランセス ヴァイレダ
サンツ， マリア クルス
ガルシア， テレサ ヨップ
オイユ， アンヘルス モー
Original Assignee
バイオキット， エセ．アー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオキット， エセ．アー． filed Critical バイオキット， エセ．アー．
Publication of JP2008502318A publication Critical patent/JP2008502318A/ja
Application granted granted Critical
Publication of JP5414972B2 publication Critical patent/JP5414972B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/20—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
JP2006546204A 2003-12-23 2004-12-23 病原体感染の検出のための組成物および方法 Expired - Fee Related JP5414972B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03380307.3 2003-12-23
EP03380307 2003-12-23
PCT/ES2004/000581 WO2005061532A1 (es) 2003-12-23 2004-12-23 Composiciones y procedimientos para detectar infección patógena

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009192620A Division JP5133306B2 (ja) 2003-12-23 2009-08-21 病原体感染の検出のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2008502318A JP2008502318A (ja) 2008-01-31
JP5414972B2 true JP5414972B2 (ja) 2014-02-12

Family

ID=34707292

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006546204A Expired - Fee Related JP5414972B2 (ja) 2003-12-23 2004-12-23 病原体感染の検出のための組成物および方法
JP2009192620A Expired - Fee Related JP5133306B2 (ja) 2003-12-23 2009-08-21 病原体感染の検出のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009192620A Expired - Fee Related JP5133306B2 (ja) 2003-12-23 2009-08-21 病原体感染の検出のための組成物および方法

Country Status (5)

Country Link
US (6) US7700727B2 (cg-RX-API-DMAC7.html)
EP (1) EP1724281B1 (cg-RX-API-DMAC7.html)
JP (2) JP5414972B2 (cg-RX-API-DMAC7.html)
ES (1) ES2405848T3 (cg-RX-API-DMAC7.html)
WO (1) WO2005061532A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1724281B1 (en) * 2003-12-23 2013-02-13 Biokit S.A. Pathogenic infection detection compositions and methods
US20060217893A1 (en) * 2005-01-07 2006-09-28 Yanbin Li Method for detecting an unknown contaminant concentration in a substance
US20090148870A1 (en) * 2006-05-18 2009-06-11 Ericson Daniel G Rapid Detection of Mycobacterium Tuberculosis and Antimicrobial Drug Resistance
US20100120016A1 (en) * 2006-09-01 2010-05-13 Yanbin Li Methods and systems for detection of contaminants
CN102365295A (zh) * 2009-01-30 2012-02-29 阿德利夫股份有限公司 构象动力肽
CN101858914B (zh) * 2010-05-19 2013-03-27 厦门大学附属中山医院 梅毒特异性总抗体胶体金免疫层析检测试剂条及其制备方法
US20130266554A1 (en) * 2010-09-16 2013-10-10 Novozymes A/S Lysozymes
RU2481101C2 (ru) * 2010-12-15 2013-05-10 Владимир Николаевич Иванов Фармацевтическая композиция, содержащая ферменты: лизоцим, пероксидазу, повиаргол и липосомы, для местного применения
EP2537858A1 (en) 2011-06-20 2012-12-26 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Small efficient cell penetrating peptides derived from the scorpion toxin maurocalcine
WO2013006795A2 (en) * 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
US20140228248A1 (en) * 2011-09-28 2014-08-14 Biomed Valley Discoveries, Inc. Methods and compositions for detecting infections
WO2013085540A2 (en) * 2011-12-09 2013-06-13 The Ohio State University Research Foundation Cry crystals for the production of antimicrobial proteins
US20130210747A1 (en) 2012-02-13 2013-08-15 University Of Southern California Methods and Therapeutics Comprising Ligand-Targeted ELPs
US20150218280A1 (en) 2012-08-10 2015-08-06 University Of Southern California CD20 scFv-ELPs METHODS AND THERAPEUTICS
US10597696B2 (en) 2013-09-18 2020-03-24 University Of Notre Dame Du Lac Detection of Niemann-Pick disease comprising detection of lysozyme and cathepsins
CN104761621B (zh) * 2014-01-06 2016-04-13 长春新悦然科技有限公司 一种抗菌蛋白
KR101933217B1 (ko) 2017-12-28 2018-12-27 (주) 에빅스젠 피부 염증 억제용 펩티드 및 이를 포함하는 피부 염증 예방 또는 치료용 조성물
CN111206025B (zh) * 2020-02-28 2022-02-15 江南大学 一种比活提高的溶菌酶突变体
US20230173030A1 (en) * 2020-05-05 2023-06-08 Phasebio Pharmaceuticals, Inc. Vasoactive intestinal peptide fusion proteins for the treatment of covid-19
CN114213551B (zh) * 2021-12-03 2023-04-11 四川农业大学 一种高表达重组生物蛋白api及其制备方法和应用
CN113881610B (zh) * 2021-12-06 2022-02-25 北京量化健康科技有限公司 多形拟杆菌bp8e及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4065354A (en) * 1974-10-10 1977-12-27 Syva Company Lysozyme conjugates for enzyme immunoassays
US4076797A (en) 1976-09-28 1978-02-28 Hoffmann-La Roche Inc. Radioimmunoassay
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4288426A (en) 1980-03-20 1981-09-08 Research Corporation Serological test for syphilis
JPS5871457A (ja) 1981-10-23 1983-04-28 Fujirebio Inc 梅毒検査用試薬の製造法
US4514498A (en) 1982-05-26 1985-04-30 The Board Of Regents, The University Of Texas System Hybrid cell lines producing monoclonal antibodies directed against Treponema
US4740467A (en) 1982-05-26 1988-04-26 Board Of Regents, The University Of Texas Methods for diagnosing syphilis
US4777133A (en) 1984-06-11 1988-10-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Device for quantitative endpoint determination in immunofluorescence using microfluorophotometry
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4894328A (en) 1986-03-26 1990-01-16 Board Of Regents, The University Of Texas System Immunodiagnostic test for syphilis and other treponemal infections
US5681934A (en) 1986-09-30 1997-10-28 Board Of Regents, The University Of Texas System 47-kilodalton antigen of Treponema pallidum
US5350842A (en) 1986-09-30 1994-09-27 Board Of Regents, The University Of Texas System DNAs encoding Treponema pallidum antigens
ES2120401T3 (es) * 1986-11-17 1998-11-01 Scios Inc Proteina recombinante amiloide relacionados con la enfermedad de alzheimer.
US5008199A (en) 1987-11-19 1991-04-16 Warner-Lambert Company Hybridoma cell line and monoclonal antibodies to Treponema denticola ATCC 33520
US5055405A (en) 1987-11-19 1991-10-08 Warner-Lambert Company Hybridoma cell line and monoclonal antibodies to Treponema species T. denticola JD-1 and Treponema 10A
NO177065C (no) * 1988-09-26 1995-07-12 Labofina Sa Framgangsmåte for framstilling av enzymatisk aktivt humant lysozym
US5514553A (en) 1989-05-22 1996-05-07 The United States Of America As Represented By The Secretary Of The Navy Production of monoclonal antibodies to Treponema denticola by hybridoma TDII, IAA11
US4959304A (en) 1989-05-22 1990-09-25 United States Of America As Represented By The Secretary Of The Navy Production of monoclonal antibodies to treponema denticola by hybridoma TDIII, IIIBB2
US5372928A (en) 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
US4997932A (en) * 1989-11-13 1991-03-05 Boehringer Mannheim Corporation Method and kit for purifying nucleic acids
US5474900A (en) 1990-03-16 1995-12-12 Sekisui Chemical Co., Ltd. Process for preparing purified syphilis antigen from Treponema palljdum
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6313094B1 (en) 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
US5155022A (en) 1991-02-08 1992-10-13 Becton, Dickinson And Company Assay for lyme disease
US5965702A (en) 1991-10-21 1999-10-12 Abbott Laboratories Borrelia burgdorferi antigens and uses thereof
DE69432791T2 (de) 1993-05-28 2004-06-03 Baylor College Of Medicine, Houston Verfahren und massenspektrometer zur desorption und ionisierung von analyten
US5578456A (en) 1994-02-28 1996-11-26 Fujirebio Inc. Anti-treponema pallidum antibody immunoassay
US5635182A (en) * 1994-06-16 1997-06-03 Genetics Institute, Inc. Method of detecting ligand interactions
US5962245A (en) * 1995-04-05 1999-10-05 The Picower Institute For Medical Research Methods for detecting the presence of advanced glycosylation endproducts
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
DE19536166C1 (de) 1995-09-29 1997-03-06 Siegfried Dr Krell Verfahren zur Bestimmung von Antikörpern gegen Treponema pallidum (Syphilis)
CA2193870C (en) * 1995-12-25 2000-07-18 Nobuyuki Ise Treponema pallidum fused antigen and assay for anti-treponema pallidum antibodies using the same fused antigen
JPH10218895A (ja) * 1997-02-14 1998-08-18 Higeta Shoyu Co Ltd 改変タンパク質、それをコードするｄｎａ、そのｄｎａを含む組換えベクター、その組換えベクターを含む形質転換体、改変タンパク質の製造法、抗トレポネーマ・パリダム抗体の測定法及び測定用試薬、梅毒感染診断薬並びに抗トレポネーマ・パリダム抗体の製造法
EP0984065A4 (en) * 1997-02-14 2002-07-24 Higeta Shoyu Kk MODIFIED PROTEINANTIGENT FROM TREPONEMA PALLADIUM.
DE19723463A1 (de) * 1997-06-04 1998-12-10 Dade Behring Marburg Gmbh Immunchemische Bestimmung von multivalenten Analyten
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
DE19749973C1 (de) 1997-11-05 1998-10-22 Klaus Dr Duering Lysozym-analoge Proteine und Peptide mit antimikrobieller Wirkung, ihre Herstellung und ihre Verwendung
US6083700A (en) * 1998-06-26 2000-07-04 Incyte Pharmaceuticals, Inc. Human goose-type lysozyme
IT1319277B1 (it) * 2000-10-24 2003-09-26 Chiesi Farma Spa Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
EP1724281B1 (en) * 2003-12-23 2013-02-13 Biokit S.A. Pathogenic infection detection compositions and methods

Also Published As

Publication number Publication date
EP1724281B1 (en) 2013-02-13
JP5133306B2 (ja) 2013-01-30
WO2005061532A1 (es) 2005-07-07
JP2008502318A (ja) 2008-01-31
US20050277181A1 (en) 2005-12-15
EP1724281A1 (en) 2006-11-22
US20060063149A1 (en) 2006-03-23
WO2005061532A8 (es) 2005-08-04
US20060270835A1 (en) 2006-11-30
ES2405848T3 (es) 2013-06-04
US20060275317A1 (en) 2006-12-07
US7700727B2 (en) 2010-04-20
US20060269976A1 (en) 2006-11-30
JP2009291208A (ja) 2009-12-17
US20060286119A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
JP5133306B2 (ja) 病原体感染の検出のための組成物および方法
KR102381478B1 (ko) 브래디키닌 매개 장애의 평가 및 치료
CN112384808B (zh) 用于减轻抗药物抗体（ada）免疫测定中的药物靶标干扰的方法
JP7592412B2 (ja) 魚介類アレルギーの診断の方法及び製品
JP2018132525A (ja) ピーナッツアレルギーの診断のための改善されたアッセイ
CN105378479A (zh) 用于预测免疫疗法的临床效果的方法
US20230168247A1 (en) Specificity enhancing reagents for covid-19 antibody testing
CN116157412A (zh) 与寡聚脂多糖结合蛋白有关的用途、方法和产品
WO2010109451A1 (en) Diagnosis of bacillus anthracis infection based on detection of bacterial secreted biomarkers
US12228578B2 (en) Rocky mountain spotted fever detection and treatment
KR101329342B1 (ko) 돼지인플루엔자 바이러스 뉴라미니다아제 검출용 항체 및 이의 용도
US20240280575A1 (en) Compositions and Methods for the Detection of Mycoplasma
BRPI0903089B1 (pt) Peptídeos recombinantes e motivos proteicos miméticos a antígenos de leishmania e suas aplicações
KR20170134978A (ko) 클라미디아 수이스의 검출을 위한 방법 및 펩타이드
EP3611183B1 (en) Epitope peptide specifically recognizing autoantibody against aquaporin 5, and use thereof
WO2022253260A1 (zh) 新型冠状病毒及其突变株中和抗体的检测试剂盒
TW202326137A (zh) 蛋白質微陣列及其用途與檢測方法
CN112180096A (zh) 用于诊断线虫感染的新测定法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100802

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101112

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101215

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20110401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131016

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131113

R150 Certificate of patent or registration of utility model

Ref document number: 5414972

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees